Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-center, randomized, double-blind, placebo controlled, parallel study evaluating the safety and physiologic effects of MIB-626 in adults at risk for age-related conditions

Next Previous
Trial Profile

A single-center, randomized, double-blind, placebo controlled, parallel study evaluating the safety and physiologic effects of MIB-626 in adults at risk for age-related conditions

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MIB-626 (Primary)
  • Indications Acute kidney injury; COVID 2019 infections; Friedreich's ataxia
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 09 Feb 2023 New trial record
  • 06 Feb 2023 Results assessing nicotinamide adenine dinucleotide augmentation in overweight or obese middle aged and older adults, published in the Journal of Clinical Endocrinology and Metabolism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top